Frontline Management of Atopic Dermatitis in Adults - Episode 13
Safety Protocols With JAK Inhibitors
Panelists discuss how the Measure Up 1 and 2 studies (Simpson 2022) showed that at 52 weeks, 82.0% to 84.9% of upadacitinib patients achieved EASI-75. Common adverse effects (AEs) included acne, cough, and headache, with 4.5% to 7.2% withdrawal rates.
Video content above in prompted by the following:
- Discuss the Measure Up 1 and 2 studies (upadacitinib) (Simpson 2022). Do you see similar results in patients who take upadacitinib in your practice? When do you recommend this treatment?
- At 52 weeks, 82.0% and 79.1% of patients taking 15 mg upadacitinib achieved EASI-75, in Measure Up 1 and 2 respectively.
- At 52 weeks, 84.9% and 84.3% of patients taking 30 mg upadacitinib achieved EASI-75, in Measure Up 1 and 2, respectively.
- The most common AEs were acne, cough, headache, herpes zoster, and creatine kinase elevation
- 4.5% of patients taking 15 mg upadacitinib withdrew due to AEs.
- 7.2% of patients taking 30 mg upadacitinib withdrew due to AEs.
